Protocolo diagnóstico y terapéutico de la anemia en un paciente oncológico

  1. Molina Villaverde, R.
  2. Herrero Fernández, M.
  3. Villalobos León, M.L.
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Ano de publicación: 2017

Título do exemplar: Enfermedades oncológicas (III) Tumores genitourinarios. Melanoma

Serie: 12

Número: 33

Páxinas: 1990-1994

Tipo: Artigo

DOI: 10.1016/J.MED.2017.04.023 DIALNET GOOGLE SCHOLAR

Outras publicacións en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumo

Abstract Introduction Approximately 40% of cancer patients have anaemia. Seventy-five percent of those receiving chemotherapy treatment will develop it in 6 months. Causes The most frequent causes are chronic disease and chemotherapy, and both can be aggravated by nutritional deficiencies and chronic bleeding. Treatment We currently have different treatments that include transfusions, erythropoiesis-stimulating agents and iron therapy.

Referencias bibliográficas

  • Ludwig H, Van Belle S, Barret-Lee P, Birgegard G, Bokemeyer C, Gascón P. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40:2293-306.
  • Aapro M, Osterborg A, Gascón P, Ludwig H, Beguin Y. Prevalence and management of cancer related anaemia, iron deficiency and the specific role of iv iron. Ann Oncol. 2012;23(8):1954-62.
  • Van Eeden R, Rapoport B. Current trends in the management of anaemia in solid tumours and haematological malignancies. Curr Support and Palliative Care. 2016;10(3):249-55.
  • Schrijvers D, de Samblanx H, Roila F. Erythropoiesis stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Guidelines for use. Ann Oncol. 2010;21Suppl5:v 244-7.
  • Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL. American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the use of epoetin and darbe poetin in adult patient with cancer. J Clin Oncol. 2010;33(20):4996-5010.
  • Aapro M, Link H, September 2007 Update on EORTC Guidelines and anemia management with erythropoiesis stimulating agents. The oncologist 2008;13Suppl3:33-6.
  • Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J. Erythropoietin or darbepoetin for patients with cancer: meta-analysis based on individual patient data. Cochrane Database Syst Rev. 2009;(3):CD007303.
  • Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P. Erythropoiesis-stimulating agents in oncology: a study-level meta-analy-sis of survival and other safety outcomes. Br J Cancer. 2010;102(2):301-13.
  • Castro J, Gascón P, Casas A, Muñoz-Langa J, Alberola V, Cucala M. Iron deficiency in patients with solid tumours: prevalence and management in clinical practice. Clin Transl Oncol. 2014;16(9):823-8.
Fonte de datos: Dialnet